NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0.15 GF Score: 20/100

NeuBase Therapeutics Inc Accelerating the Genetic Revolution with a New Class of Synthetic Medicines Transcript

Dec 23, 2020 / NTS GMT
Release Date Price: $157.4 (+0.90%)
John Heerdink
Tribe Public - Analyst

Good morning, everyone or good evening, depending on where you guys are coming in from today. This is John Heerdink. I'm the Founder and Managing Member of Tribe Public. And I'm excited again today to have Dietrich Stephan, Founder, CEO of NeuBase Therapeutics. NeuBase trades on the Nasdaq, symbol NBSE.

I'm proud to be an investor in the company, been in since the company went public as I participated in around and I've added an investment sense. Again, thank you all from the Tribe that come in from around the world, and I look forward to hearing from you after this call.(Conference Instructions)

But I'm going to allow Dietrich to introduce himself again, for those of you that haven't met him. And at the same time, please do send your questions. He's going to do about a 15-, 20-, 30-minute, depending on the presentation, how quickly it goes. And he's had some exciting data that he's going to share with us that came out at the end of last week, and I think will accelerate his company and platform as he moves forward.

So Dietrich, thanks again

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot